Comparing Equillium (NASDAQ:EQ) and DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares DBV Technologies and Equillium’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Equillium	N/A	-41.15%	-38.29%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for DBV Technologies and Equillium, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	1	5	0	2.57
Equillium	1	1	7	2	2.91

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 319.55%. Equillium has a consensus target price of $7.57, suggesting a potential upside of 353.38%. Given Equillium’s stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than DBV Technologies.

Valuation & Earnings

This table compares DBV Technologies and Equillium”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64 million	128.88	-$146.95 million	($3.51)	-3.29
Equillium	$41.10 million	2.58	-$22.40 million	($0.20)	-8.35

Equillium has higher revenue and earnings than DBV Technologies. Equillium is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

DBV Technologies has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Summary

Equillium beats DBV Technologies on 12 of the 15 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.